PDS BIOTECHNOLOGY CORPORATION - COMMON STOCK

PDS Biotech Leadership to Participate in March Conferences

11 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

07 Mar 2025 08:45:00 By Nasdaq GlobeNewswire

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

27 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

26 Feb 2025 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

24 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

20 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

05 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

06 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

03 Dec 2024 08:00:33 By Nasdaq GlobeNewswire

PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results

14 Nov 2024 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

06 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine

22 Oct 2024 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

02 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024

16 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

09 Sep 2024 08:00:47 By Nasdaq GlobeNewswire

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results

13 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual Meeting

08 Aug 2024 08:00:01 By Nasdaq GlobeNewswire

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

07 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

PDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024

05 Aug 2024 08:00:00 By Nasdaq GlobeNewswire